Advanced in B-Cell Lymphoma

Aart Beeker

Spaarne Gasthuis
Hoofddorp, NH, NL 
Advanced in B-Cell Lymphoma
Spaarne Gasthuis
Hoofddorp, NH, NL 
OverviewLocationsClinical Research

Overview

Aart Beeker practices in Hoofddorp, Netherlands. Beeker is rated as an Advanced expert by MediFind in the treatment of B-Cell Lymphoma. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Agranulocytosis, and Non-Hodgkin Lymphoma.

Their clinical research consists of co-authoring 66 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 8 articles and participated in 2 clinical trials in the study of B-Cell Lymphoma.

Locations

Spaarne Gasthuis
Hoofddorp, NH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.
A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2025
Intervention Type: Drug, Other, Procedure, Radiation
Study Phase: Not Applicable
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
The Effect of Individualized NUTritional Counselling on Muscle Mass and Treatment Outcome in Patients With Metastatic COLOrectal Cancer Undergoing Chemotherapy: the COLONUT Study
The Effect of Individualized NUTritional Counselling on Muscle Mass and Treatment Outcome in Patients With Metastatic COLOrectal Cancer Undergoing Chemotherapy: the COLONUT Study
Enrollment Status: Completed
Publish Date: December 21, 2018
Intervention Type: Procedure
Study Phase: Not Applicable
Influence of Exceptional Patient Characteristics on Everolimus Exposure
Influence of Exceptional Patient Characteristics on Everolimus Exposure
Enrollment Status: Completed
Publish Date: December 07, 2018
Intervention Type: Drug
Study Phase: Phase 4
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: April 07, 2017
Intervention Type: Drug
Study Phase: Not Applicable
View 6 Less Clinical Trials

66 Total Publications

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Journal: Nature
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Beeker's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile